Last 23 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.51 | — | — | — | — | 0.87 | — | — | — | — | — | — | — | — | — | — | — | — | — | 42.73 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -44.3% | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | 76.51 | — | 27.26 | 11.11 | 33.42 | 6.52 | 122.34 | 9.54 | 3.44 | 2.10 | 2.45 | 3.65 | 7.68 |
| — | — | — | — | — | — | — | — | +128.9% | — | -77.7% | +16.4% | +871.9% | +210.1% | +4884.2% | +161.4% | -55.2% | -71.8% | -58.7% | -42.1% | — | |
| P/B Ratio | 1.23 | 1.40 | 1.45 | 0.90 | 1.18 | 0.95 | 1.36 | 0.59 | 1.35 | 0.68 | 0.62 | 0.79 | 0.71 | 2.16 | 2.12 | 0.91 | 0.96 | 0.98 | 1.68 | 4.18 | 8.81 |
| — | +47.8% | +6.4% | +52.9% | -13.0% | +40.0% | +118.8% | -25.7% | +89.9% | -68.7% | -70.7% | -12.6% | -25.6% | +119.7% | +26.4% | -78.2% | -89.1% | -92.1% | -85.2% | +7.0% | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 75.09 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | 0.73 | — | — | — | — | — | — | — | — | — | — | — | — | — | 34.25 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -73.8% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | -585.0% | — | -288.4% | -110.1% | -209.5% | 22.3% | -943.4% | -58.9% | 57.3% | 74.7% | -35.2% | 100.0% | 3.7% |
| — | — | — | — | — | — | — | — | -179.2% | — | +69.4% | -87.1% | -465.9% | -70.2% | -2581.8% | -158.9% | +1443.1% | -23.2% | -1251.7% | +308.3% | — | |
| Operating Margin | — | — | — | — | — | — | — | — | -8726.3% | — | -3877.0% | -1205.9% | -6188.0% | -420.1% | -7573.4% | -1273.8% | -363.7% | -217.5% | -103.0% | -56.8% | -66.4% |
| — | — | — | — | — | — | — | — | -41.0% | — | +48.8% | +5.3% | -1601.2% | -93.2% | -7250.7% | -2141.5% | -447.7% | -700.2% | -553.1% | -1281.9% | — | |
| Net Margin | — | — | — | — | — | — | — | — | -9934.5% | — | -2787.7% | -532.1% | -7493.8% | -402.7% | -8046.1% | -1265.5% | -364.4% | -197.1% | -75.2% | 8.4% | -104.5% |
| — | — | — | — | — | — | — | — | -32.6% | — | +65.4% | +58.0% | -1956.4% | -104.3% | -10598.7% | -15250.9% | -248.9% | -612.6% | -365.5% | +0.3% | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 15.0% | -10.5% | -10.2% | -10.0% | -10.7% | 51.3% | -60.5% | -21.9% | -36.2% | -24.9% | -14.8% | -9.1% | -63.0% | -29.2% | -31.2% | -26.5% | -25.5% | -20.9% | -12.2% | 2.5% | -31.4% |
| — | -120.4% | +83.2% | +54.6% | +70.6% | +305.9% | -308.2% | -140.3% | +42.5% | +14.6% | +52.5% | +65.6% | -146.8% | -39.7% | -156.0% | -1173.4% | +18.6% | -88.6% | -205.8% | +91.7% | — | |
| ROA | 12.2% | -9.4% | -9.2% | -9.0% | -9.5% | 42.6% | -29.6% | -12.6% | -23.3% | -17.9% | -11.0% | -6.5% | -40.7% | -16.0% | -17.6% | -15.7% | -15.2% | -12.7% | -7.5% | 1.3% | -17.5% |
| — | -122.1% | +68.8% | +29.1% | +59.3% | +337.9% | -169.2% | -95.1% | +42.9% | -11.8% | +37.5% | +58.8% | -167.3% | -26.2% | -133.5% | -1284.7% | +12.8% | -64.4% | -119.9% | +10.4% | — | |
| ROIC | -43.5% | -9.4% | -8.3% | -8.3% | -8.2% | -12.1% | -39.1% | -36.5% | -27.8% | -25.5% | -19.5% | -33.6% | -117.4% | -22.8% | -28.3% | -28.7% | -22.9% | -20.4% | -18.0% | -24.9% | -24.5% |
| — | +22.6% | +78.9% | +77.2% | +70.5% | +52.4% | -100.7% | -8.6% | +76.3% | -11.9% | +31.1% | -17.2% | -411.5% | -11.7% | -57.1% | -15.1% | +6.3% | -125.5% | -500.0% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.02 | 0.02 | 0.03 | 0.04 | 0.04 | 0.53 | 0.32 | 0.18 | 0.12 | 0.12 | 0.10 | 0.10 | 0.30 | 0.28 | 0.22 | 0.19 | 0.23 | 0.20 | 0.19 | 0.22 |
| — | -37.8% | -95.5% | -91.4% | -78.2% | -69.4% | +361.1% | +207.0% | +74.4% | -59.8% | -59.0% | -53.9% | -46.0% | +30.5% | +41.9% | +19.7% | -13.6% | +20.2% | +10.3% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 9.46 | 7.28 | 9.22 | 11.45 | 9.46 | 10.50 | 0.87 | 1.69 | 2.98 | 3.69 | 5.24 | 5.65 | 5.45 | 0.34 | 0.82 | 1.10 | 1.47 | 1.30 | 1.72 | 1.98 | 1.90 |
| — | -30.6% | +957.8% | +578.1% | +217.3% | +184.4% | -83.4% | -70.1% | -45.3% | +986.9% | +540.8% | +414.0% | +269.6% | -73.8% | -52.4% | -44.5% | -22.3% | -38.0% | -36.9% | -85.9% | — | |
| Quick Ratio | 9.46 | 7.28 | 9.22 | 11.45 | 9.46 | 10.50 | 0.87 | 1.69 | 2.98 | 3.69 | 5.24 | 5.65 | 5.45 | 0.34 | 0.82 | 1.10 | 1.47 | 1.30 | 1.72 | 1.98 | 1.90 |
| — | -30.6% | +957.8% | +578.1% | +217.3% | +184.4% | -83.4% | -70.1% | -45.3% | +986.9% | +540.8% | +414.0% | +269.6% | -73.8% | -52.4% | -44.5% | -22.3% | -38.0% | -36.9% | -85.9% | — | |
| Interest Coverage | 56.15 | — | -361.76 | -299.73 | -264.68 | 1050.74 | -156.19 | -73.70 | -159.77 | -131.62 | -77.78 | -64.81 | -292.49 | -72.21 | -90.36 | -78.60 | -88.50 | -99.19 | -91.85 | 15.97 | -24.94 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 23 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SABS stock.
SAB Biotherapeutics, Inc.'s current P/E is -3.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking SAB Biotherapeutics, Inc.'s business trajectory between earnings reports.